RxDoctor Payments DataLook up a doctor →

Abigail Lawler, MD

Neurology · Fairfax, VANPI 1568789741

Payments from drug & device makers

$107,263in general payments, 2019–2025

Across 958 payments — averaging $111.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$67K
  • Amneal Pharmaceuticals LLC$15K
  • MDD US Operations, LLC$11K
  • Sunovion Pharmaceuticals Inc.$4K
  • Acadia Pharmaceuticals Inc$982
  • Teva Pharmaceuticals USA, Inc.$741
  • plus $8K from 47 others

What the payments were for

  • Consulting fees$5,6505%
  • Speaking & faculty fees$72,57968%
  • Travel & lodging$9,8509%
  • Food & beverage$17,79417%
  • Education$1,3901%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,263 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$254,288
Medicare patients
524
Services billed
3,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate243$1,522,967
RytaryCarbidopa/Levodopa277$437,327
Rivastigmine430$118,804
NourianzIstradefylline24$82,416
GocovriAmantadine Hcl26$70,804
NuedextaDextromethorphan Hbr/Quinidine29$53,156
CrexontCarbidopa/Levodopa35$42,523
OngentysOpicapone24$36,485
NeuproRotigotine17$34,618
InbrijaLevodopa11$33,530
Rasagiline Mesylate182$31,904
NamzaricMemantine Hcl/Donepezil Hcl20$23,917
QuliptaAtogepant17$19,062
Carbidopa21$15,633
Memantine Hcl322$15,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$982$1,522,967243 claims
Amneal Pharmaceuticals LLCRytary, Crexont$14,742$479,850312 claims
Kyowa Kirin, Inc.Nourianz$277$82,41624 claims
MDD US Operations, LLCGocovri$11,445$70,80426 claims
Avanir Pharmaceuticals, Inc.Nuedexta$280$53,15629 claims
AbbVieNamzaric, Qulipta$67,251$42,97937 claims
Neurocrine Biosciences, Inc.Ongentys$468$36,48524 claims
UCB, Inc.Neupro$707$34,61817 claims
Acorda Therapeutics, IncInbrija$210$33,53011 claims
Lilly USA, LLCOlanzapine$305$40823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →